Literature DB >> 19109588

Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis.

Braden J Manns1, Michael W Walsh, Bruce F Culleton, Brenda Hemmelgarn, Marcello Tonelli, Melissa Schorr, Scott Klarenbach.   

Abstract

We conducted a randomized controlled trial to compare the quality of life of 52 patients undergoing nocturnal hemodialysis and conventional hemodialysis. Quality of life was measured using a number of established methods including the Kidney Disease Quality of Life Short Form and the preference-based Euroqol EQ-5D questionnaire (whose scores varied from 0 to 1). The primary outcome was a change in the Euroqol EQ-5D index scores between baseline and 6 months. We performed additional analyses comparing change in quality of life from pre-randomization (when patients were unaware of treatment allocation) to 6 months. Other analyses considered the impact of nocturnal hemodialysis on four pre-selected Kidney Disease Quality of Life Short Form domains, and the longer term impact of nocturnal hemodialysis on quality of life. Compared with conventional hemodialysis, nocturnal hemodialysis increased Euroqol-EQ-5D index scores by 0.05, which was not significantly different from baseline. When six-month values were compared with pre-randomization values rather than baseline values, the between group difference was larger (0.12) though it was still not statistically significant (P=.06). Nocturnal hemodialysis was associated with clinically and statistically significant improvements in selected kidney-specific quality of life domains (P=.01 for effects of kidney disease; P=.02 for burden of kidney disease). Our primary quality of life analysis did not demonstrate a statistically significant change between nocturnal hemodialysis and conventional hemodialysis, though statistically significant and clinically important changes in some secondary kidney-disease- specific measures were observed.

Entities:  

Mesh:

Year:  2008        PMID: 19109588     DOI: 10.1038/ki.2008.639

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Design and rationale of health-related quality of life and patient-reported outcomes assessment in the Frequent Hemodialysis Network trials.

Authors:  Manisha Jhamb; Manjula K Tamura; Jennifer Gassman; Amit X Garg; Robert M Lindsay; Rita S Suri; George Ting; Fredric O Finkelstein; Scott Beach; Paul L Kimmel; Mark Unruh
Journal:  Blood Purif       Date:  2011-01-10       Impact factor: 2.614

2.  Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort.

Authors:  Robert P Pauly; Katerina Maximova; Jennifer Coppens; Reem A Asad; Andreas Pierratos; Paul Komenda; Michael Copland; Gihad E Nesrallah; Adeera Levin; Anne Chery; Christopher T Chan
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

3.  Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial.

Authors:  Michael V Rocco; John T Daugirdas; Tom Greene; Robert S Lockridge; Christopher Chan; Andreas Pierratos; Robert Lindsay; Brett Larive; Glenn M Chertow; Gerald J Beck; Paul W Eggers; Alan S Kliger
Journal:  Am J Kidney Dis       Date:  2015-04-08       Impact factor: 8.860

Review 4.  Chronic Hemodialysis Therapy in the West.

Authors:  Michael V Rocco
Journal:  Kidney Dis (Basel)       Date:  2015-11-18

5.  Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials.

Authors:  Rita S Suri; Brett Larive; Amit X Garg; Yoshio N Hall; Andreas Pierratos; Glenn M Chertow; Irina Gorodetskeya; Alan S Kliger
Journal:  Nephrol Dial Transplant       Date:  2011-03-18       Impact factor: 5.992

Review 6.  Assessing and improving the health-related quality of life of patients with ESRD.

Authors:  Fredric O Finkelstein; Kelli L Arsenault; Ana Taveras; Kwabena Awuah; Susan H Finkelstein
Journal:  Nat Rev Nephrol       Date:  2012-10-23       Impact factor: 28.314

7.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

8.  Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial.

Authors:  Scott Klarenbach; Marcello Tonelli; Robert Pauly; Michael Walsh; Bruce Culleton; Helen So; Brenda Hemmelgarn; Braden Manns
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

9.  Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials.

Authors:  Mark L Unruh; Brett Larive; Glenn M Chertow; Paul W Eggers; Amit X Garg; Jennifer Gassman; Maria Tarallo; Fredric O Finkelstein; Paul L Kimmel
Journal:  Am J Kidney Dis       Date:  2013-01-15       Impact factor: 8.860

10.  Varying Association of Extended Hours Dialysis with Quality of Life.

Authors:  Brendan Smyth; Oliver van den Broek-Best; Daqing Hong; Kirsten Howard; Kris Rogers; Li Zuo; Nicholas A Gray; Janak R de Zoysa; Christopher T Chan; Hongli Lin; Ling Zhang; Jinsheng Xu; Alan Cass; Martin Gallagher; Vlado Perkovic; Meg Jardine
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.